Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to $12.4 million.

  • Traws Pharma's Liabilities and Shareholders Equity rose 3924.57% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.1 million, marking a year-over-year increase of 527.62%. This contributed to the annual value of $25.0 million for FY2024, which is 1004.72% up from last year.
  • As of Q3 2025, Traws Pharma's Liabilities and Shareholders Equity stood at $12.4 million, which was up 3924.57% from $15.6 million recorded in Q2 2025.
  • In the past 5 years, Traws Pharma's Liabilities and Shareholders Equity registered a high of $60.0 million during Q3 2021, and its lowest value of $8.9 million during Q3 2024.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $30.5 million (2023), whereas its average is $32.9 million.
  • Per our database at Business Quant, Traws Pharma's Liabilities and Shareholders Equity soared by 17758.43% in 2021 and then tumbled by 6695.02% in 2024.
  • Over the past 5 years, Traws Pharma's Liabilities and Shareholders Equity (Quarter) stood at $55.5 million in 2021, then decreased by 29.03% to $39.4 million in 2022, then tumbled by 42.39% to $22.7 million in 2023, then rose by 10.05% to $25.0 million in 2024, then tumbled by 50.15% to $12.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $12.4 million for Q3 2025, versus $15.6 million for Q2 2025 and $19.1 million for Q1 2025.